Subsequently, in addition to expanding the structure-activity-relationship around QC-01-175 and demonstration of efficacy with VHL-based degraders in tauopathy-patient iPSC neuronal models for the first time [103], as well as a diverse range of small molecules claimed in patent applications [104], several other groups have reported in the academic literature PROTACs that efficiently degrade tau. This evidence concerns the gene MAPT and tauopathy.